Peptides DB
Research-centric peptide and protocol reference hub

Abaloparatide (Tymlos) record · updated 17h ago

Healing & recoveryGrade A · human clinicalResearch use only
All 5 studiesJump to the evidenceCompare
What is Abaloparatide (Tymlos) used for?

Abaloparatide (Tymlos) is a synthetic PTHrP analog and FDA-approved anabolic agent for osteoporosis, building bone via selective PTH1R activation.

Primarily researched for · Healing & recovery

Development stage

where Abaloparatide (Tymlos) sits between preclinical work and regulatory approval
  1. 1Current
    Preclinical
    Animal / in-vitro work
  2. 2Not reached
    Phase 1
    Safety in humans
  3. 3Not reached
    Phase 2
    Efficacy signal
  4. 4Not reached
    Phase 3
    Confirmatory trials
  5. 5Not reached
    Approved
    Cleared by a regulator

Stage is inferred from the highest trial phase in the indexed corpus and 20 registered trials. It describes the research record, not a recommendation.

Identity
NameAbaloparatide (Tymlos)
Full name—
Sequence—
ClassHealing
Research levelExtensively Studied
Discovered byCurated master list · 2026
Pharmacology
Mechanism—
Route—
Half-life—
Time to peak—
Duration—
Extraction confidence—
Effect profile · 0–5
Healing & recovery: Healing 5.0, Muscle 0.0, Metabolic 0.0, Neuro 0.0, Sleep 0.0, Immune 0.0, Skin 0.0Healing & recovery — 5.0 / 5HealingMuscleMetabolicNeuroSleepImmuneSkin5.00.00.00.00.00.00.0
These seven scores are generated by the Librarian — an autonomous agent running GPT-4o mini over the indexed studies, trials and label data for this compound. No human assigns them and no community vote moves them. Last recomputed Jul 27, 2026. How this works →
Research stats
Total studies5
Human / animal / cellular4 / 0 / 0
Highest trial phase—
Years covered2025–2026
Latest study8d ago
Publication history
20252026
Research funding
—no NIH grants found
Safety signals
FAERS reportsnone recorded
Serious AEs in animal work—
Community reports—
Positive —Neutral —Negative —
Records

Study register

5 rowsOpen in the library →
StudyTypeYearSummary depth
Bone Optimization for Perioperative Spine Patients: A Multidisciplinary Approach at a Single Academic Center.
Finding60% demonstrated improved bone mineral density, with an average T-score gain of 0.6 ± 0.5.
Human2025Full text read0.80
Individualized Fracture Prevention for Postmenopausal Women with Osteopenia.
FindingNot reported in abstract.
review2025Full text read0.70
Real-world evidence indicates romosozumab use is associated with a greater reduction in osteoporotic fractures than PTH (1-34) analogs in women.
FindingHR for osteoporotic fractures in ROMO users vs PTH receptor agonists: 0.711, 95% CI: 0.542-0.931.
Human2026Full text read0.80
Novel 360° lumbar arthroplasty: Surgical technique and procedural details.
FindingTotal VAS score decreased by 9 points (89% reduction), n=24.
Human2026Full text read0.70
The Anabolic-First Strategy in Osteoporosis: A Systematic Review and Meta-Analysis of Fracture Outcomes in Patients at Very High Fracture Risk.
Finding0.43 (95% CI 0.34-0.54) pooled summary estimate for vertebral fractures.
Human2026Full text read0.90